Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group

被引:40
作者
Efficace, Fabio [1 ]
Breccia, Massimo [2 ]
Saussele, Susanne [3 ]
Kossak-Roth, Ute [3 ]
Cardoni, Annarita [1 ]
Caocci, Giovanni [4 ]
Chie, Weichu [5 ,6 ]
Naeem, Adel [7 ]
Nicolatou-Galitis, Ourania [8 ]
Cocks, Kim [9 ]
Vignetti, Marco [1 ]
Baccarani, Michele [10 ]
Mandelli, Franco [1 ]
Sprangers, Mirjam [11 ]
机构
[1] GIMEMA Data Ctr, Italian Grp Adult Hematol Dis GIMEMA, Hlth Outcomes Res Unit, I-00161 Rome, Italy
[2] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy
[3] Univ Heidelberg, Med Fak Mannheim, D-6800 Mannheim, Germany
[4] Univ Cagliari, Dept Internist Med Sci, Cagliari, Italy
[5] Natl Taiwan Univ, Coll Publ Hlth, Dept Publ Hlth, Taipei 10764, Taiwan
[6] Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Prevent Med, Taipei 10764, Taiwan
[7] Univ Baghdad, Dept Hematol, Baghdad, Iraq
[8] Univ Athens, Sch Dent, Clin Hosp Dent, Dent Oncol Unit, Athens, Greece
[9] Univ York, York Trials Unit, York YO10 5DD, N Yorkshire, England
[10] Univ Bologna, St Orsola Malpighi Hosp, Dept Haematol & Oncol L&A Seragnoli, Bologna, Italy
[11] Univ Amsterdam, Dept Med Psychol, Amsterdam, Netherlands
关键词
Quality of life; Chronic myeloid leukemia; Targeted therapies; IMATINIB; PROVIDERS; OUTCOMES; CANCER;
D O I
10.1007/s00277-012-1458-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective of this study was to investigate the health-related quality of life (HRQOL) aspects valued the most by patients with chronic myeloid leukemia (CML) receiving targeted therapies (TT), and to compare their perception with that of health-care professionals' (HCPs). Semi-structured interviews were conducted with 137 CML patients receiving TT from five different countries. An additional sample of 99 CML patients, completing an online interview, was considered for supportive analyses. A sample of 59 HCPs from 12 countries also participated in the study. Patients and HCPs were asked to rate and rank the importance of a predefined list of 74 HRQOL aspects of potential relevance for CML patients. Patients and HCPs agreed that the following five aspects are most important: fatigue, muscle cramps, swelling, worries, and uncertainty about health condition in the future, and importance of social support in coping with the disease. However, the difference in rankings between the two groups was substantial with respect to other HRQOL aspects investigated. Patients valued some issues related to symptoms much higher than HCPs, thus suggesting that a better symptom management could be the crucial aspects to improve HRQOL of CML patients.
引用
收藏
页码:1371 / 1381
页数:11
相关论文
共 23 条
[1]   Use of Patient-Reported Outcomes to Improve the Predictive Accuracy of Clinician-Reported Adverse Events [J].
Basch, Ethan ;
Bennett, Antonia ;
Pietanza, M. Catherine .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (24) :1808-1810
[2]   Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia [J].
Cortes, Jorge E. ;
Jones, Dan ;
O'Brien, Susan ;
Jabbour, Elias ;
Ravandi, Farhad ;
Koller, Charles ;
Borthakur, Gautam ;
Walker, Brenda ;
Zhao, Weiqiang ;
Shan, Jianqin ;
Kantarjian, Hagop .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :398-404
[3]  
De Haes J., 1988, Psychosocial Oncology, P61
[4]   Patient and Provider-Reported Symptoms in the Post-cART Era [J].
Edelman, E. J. ;
Gordon, K. ;
Justice, A. C. .
AIDS AND BEHAVIOR, 2011, 15 (04) :853-861
[5]   Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes [J].
Efficace, F. ;
Cocks, K. ;
Breccia, M. ;
Sprangers, M. ;
Meyers, C. A. ;
Vignetti, M. ;
Baccarani, M. ;
Mandelli, F. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 81 (02) :123-135
[6]  
Efficace F, 2011, BLOOD, V118
[7]   Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population [J].
Efficace, Fabio ;
Baccarani, Michele ;
Breccia, Massimo ;
Alimena, Giuliana ;
Rosti, Gianantonio ;
Cottone, Francesco ;
Deliliers, Giorgio Lambertenghi ;
Barate, Claudia ;
Rossi, Antonella Russo ;
Fioritoni, Giuseppe ;
Luciano, Luigia ;
Turri, Diamante ;
Martino, Bruno ;
Di Raimondo, Francesco ;
Dabusti, Melissa ;
Bergamaschi, Micaela ;
Leoni, Pietro ;
Simula, Maria Pina ;
Levato, Luciano ;
Ulisciani, Stefano ;
Veneri, Dino ;
Sica, Simona ;
Rambaldi, Alessandro ;
Vignetti, Marco ;
Mandelli, Franco .
BLOOD, 2011, 118 (17) :4554-4560
[8]   Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib [J].
Gambacorti-Passerini, Carlo ;
Antolini, Laura ;
Mahon, Francois-Xavier ;
Guilhot, Francois ;
Deininger, Michael ;
Fava, Carmen ;
Nagler, Arnon ;
Della Casa, Chiara Maria ;
Morra, Enrica ;
Abruzzese, Elisabetta ;
D'Emilio, Anna ;
Stagno, Fabio ;
le Coutre, Philipp ;
Hurtado-Monroy, Rafael ;
Santini, Valeria ;
Martino, Bruno ;
Pane, Fabrizio ;
Piccin, Andrea ;
Giraldo, Pilar ;
Assouline, Sarit ;
Durosinmi, Muheez A. ;
Leeksma, Onno ;
Pogliani, Enrico Maria ;
Puttini, Miriam ;
Jang, Eunjung ;
Reiffers, Josy ;
Valsecchi, Maria Grazia ;
Kim, Dong-Wook .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (07) :553-561
[9]   Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases [J].
Harris, Kristin ;
Chow, Edward ;
Zhang, Liying ;
Velikova, Galina ;
Bezjak, Andrea ;
Wu, Jackson ;
Barton, Michael ;
Sezer, Orhan ;
Eek, Richard ;
Shafiq, Jesmin ;
Yee, Albert ;
Clemons, Mark ;
Brundage, Michael ;
Hoskin, Peter ;
van der Linden, Yvette ;
Johnson, Colin D. ;
Bottomley, Andrew .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (14) :2510-2518
[10]   Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease [J].
Hochhaus, Andreas .
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, :128-135